SC
JAZZ icon

SummitTX Capital’s Jazz Pharmaceuticals JAZZ Stock Holding History

SummitTX Capital’s Portfolio JAZZ Stock Details JAZZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$13.8M Sell
73,222
-53,573
-42% -$9.36M 0.43% 37
2025
Q4 		$21.6M Buy
126,795
+103,790
+451% +$15.9M 0.65% 22
2025
Q3 		$3.03M Sell
23,005
-9,135
-28% -$1.1M 0.13% 182
2025
Q2 		$3.41M Buy
32,140
+17,740
+123% +$1.93M 0.15% 168
2025
Q1 		$1.79M Buy
+14,400
New +$1.88M 0.08% 271

Other funds holding JAZZ

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

SummitTX Capital's JAZZ Position: Q1 2026 in Review

SummitTX Capital reduced its Jazz Pharmaceuticals (JAZZ) stake by 42% in Q1 2026, selling an estimated $9.36M and leaving 73,222 shares worth $13.8M. The position accounts for 0.43% of the portfolio, ranked #37.

SummitTX Capital first reported a position in JAZZ in Q1 2025 and has held it in 5 quarters since. The position peaked at $21.6M in Q4 2025. 570 funds tracked by Wall St. Rank hold JAZZ as of Q1 2026.

  • SummitTX Capital held 73,222 shares of Jazz Pharmaceuticals worth $13.8M as of Q1 2026.
  • SummitTX Capital sold 53,573 Jazz Pharmaceuticals shares in Q1 2026, an estimated $9.36M.
  • Jazz Pharmaceuticals made up 0.43% of SummitTX Capital's portfolio in Q1 2026, its #37 holding.
  • SummitTX Capital first reported a position in Jazz Pharmaceuticals in Q1 2025 and has held it in 5 quarters since.
  • SummitTX Capital's Jazz Pharmaceuticals position peaked at $21.6M in Q4 2025.
  • 570 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q1 2026.

Based on SummitTX Capital's 13F filing for Q1 2026, filed 15 May 2026.